Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Amarin Corp Plc (NQ: AMRN)
7.140 USD  -0.090 (-1.24%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 17, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Amarin Corp Plc
 
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
VFC's Stock House Weekly Stock Watch, Week Of 13 May 2013
May 12, 2013
from EmailWire.Com Press Releases
Photo Release -- Amarin Reports First Quarter 2013 Financial Results and Provides Update on Operations
May 09, 2013
Conference Call Set for 4:30 p.m. EDT Today Read More
from GlobeNewswire News Releases
Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013
May 03, 2013
from GlobeNewswire News Releases
Amarin Announces Approval of Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
April 30, 2013
from GlobeNewswire News Releases
Critical Alerts For American International Group, Bunge, Cliffs Natural Resources, Amarin, and ImmunoGen Released By InvestorsObserver
April 29, 2013
from PR Newswire
Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia
April 23, 2013
Submission for Indication Studied in the ANCHOR Phase 3 Clinical Trial Under Special Protocol Assessment Agreement With FDA Read More
from GlobeNewswire News Releases
VFC's Stock House: SanuWave Health Boosts Long Term Potential With Short Term Catalysts Looming
April 23, 2013
from EmailWire.Com Press Releases
Amarin Announces Approval of Supplemental New Drug Application for Chemport as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
April 18, 2013
from GlobeNewswire News Releases
Amarin, Pharmacyclics, Anthera Pharma, Star Scientific, and Impax Laboratories Under StockCall's Microscope
April 16, 2013
from PR Newswire
Amarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa(R)
April 08, 2013
from GlobeNewswire News Releases
Downtrending Healthcare Stocks - Magellan Health Services (MGLN), Vanguard Health (VHS), Amarin (AMRN)
March 26, 2013
from SBWire Direct - Latest Press Releases
Prescription for Success: Commercialization Efforts, Acquisitions and Enhanced Patent Protection - Research Report on PAREXEL International, Ironwood Pharmaceuticals, Opko Health, Amarin Corporation,
March 19, 2013
from PR Newswire
Amarin, Celgene, GlaxoSmithKline, Spectrum Pharma, and Geron Briefing and Review
March 18, 2013
from PR Newswire
VFC's Stock House Weekly Stock Watch, Week of 11 March 2013
March 11, 2013
from EmailWire.Com Press Releases
Best of Drug Manufacturers-Other Industry: Amarin (AMRN), Prana (PRAN), Teva Pharmaceutical (TEVA)
March 07, 2013
category Stocks
from TransWorldNews Current Releases
Best of Drug Manufacturers-Other Industry: Amarin (AMRN), Prana (PRAN), Teva Pharmaceutical (TEVA)
March 07, 2013
category Stocks
from TransWorldNews Current Releases
Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,111 Related to Vascepa(R) and Planned ANCHOR Indication
March 07, 2013
Broadens ANCHOR Vascepa Claims With a Wider Range of EPA Concentrations Read More
from GlobeNewswire News Releases
U.S. Food and Drug Administration Approved 30% More Drugs in 2012 Than the Year Previous
March 05, 2013
RDInvesting Provides Stocks Research on Amarin and MEI Pharma Read More
from Marketwired News Releases
VFC's Stock House Weekly Stock Watch, Week of 4 March
March 04, 2013
from EmailWire.Com Press Releases
Amarin Reports Fourth Quarter and Year-End 2012 Financial Results and Provides Update on Operations
February 28, 2013
Conference Call Set for 4:30 p.m. EST Today Read More
from GlobeNewswire News Releases
Amarin Announces Submission of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides With Mixed Dyslipidemia
February 26, 2013
Submission for Indication Studied in the ANCHOR Phase 3 Clinical Trial Under Special Protocol Assessment Agreement With FDA Read More
from GlobeNewswire News Releases
VFC's Stock House Weekly Stock Watch, Week of 25 February
February 25, 2013
from EmailWire.Com Press Releases
Amarin to Report Fourth Quarter and Year-End 2012 Results and Host Conference Call on February 28, 2013
February 22, 2013
from GlobeNewswire News Releases
Amarin to Present at the CITI 2013 Global Healthcare Conference
February 21, 2013
from GlobeNewswire News Releases
Amarin and Forest Laboratories Under Review: Drug Makers Face Growing Generic Competition
February 15, 2013
from PR Newswire
High Profile HealthCare Companies: Leading Pharma Company Secures New Patents
February 14, 2013
from PR Newswire
Free Research Report on Lions Gate Entertainment Corp., Omega HealthCare Investors, Inc., Willis Group Holdings Public Limited Company, Amarin Corp. Plc and WPP PLC
February 13, 2013
from Marketwired News Releases
Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,129 Related to Vascepa(R) and FDA Approved MARINE Indication
February 12, 2013
Broadens Vascepa Claims With a Wider Range of EPA Concentrations Read More
from GlobeNewswire News Releases
Amarin to Present at the Leerink Swann Global Healthcare Conference 2013
February 07, 2013
from GlobeNewswire News Releases
The Real Story Behind DNDN, AMRN, ASML and CYCC
February 07, 2013
from Marketwired News Releases
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here